Novo Nordisk's Weight Loss Injection Pen: What It Does and How to Use It

Picture this: you're sitting on the edge of your bed with the pen, the leaflet, and a lot of questions

Most people's first injection takes far longer than it needs to, not because the technique is complicated, but because nobody wants to get it wrong. The good news is the Wegovy pen is designed to make that difficult. It is pre-filled with a fixed dose, meaning there is no cartridge to load and no plunger to prime. You remove the cap, apply the pen to the injection site, press the button, and hold it in place until the window confirms the dose has been delivered. That's essentially it.

The three licensed sites (abdomen, outer thigh, upper arm) each offer a slightly different experience. The abdomen is the most commonly used because it's accessible and has consistent subcutaneous tissue. The outer thigh works well if the abdomen is tender from recent injections. The upper arm is an option but can be trickier to reach without assistance. Whatever site you choose, rotating the exact spot each week is important: injecting repeatedly into the same small area can cause lumpy or hardened tissue that slows absorption.

One misconception worth clearing up gently: many people assume the injection itself will be painful in a way they associate with blood tests. In practice, the needle on a subcutaneous pen is very fine and short, most describe it as a mild pinch, if anything at all. Pinching up the skin before injecting (especially on the abdomen) further reduces sensation. Cleaning the site with an alcohol swab first is good practice; pre-saturated swabs are a convenient way to keep this part of the routine simple.

For a detailed walkthrough of the full injection process, our guide to the weight loss injectable pen covers each step in plain language.

What the Wegovy pen is actually doing once it's under the skin

Semaglutide, the medicine inside the weight loss injection pen from Novo Nordisk, acts on GLP-1 receptors in the brain and gut. GLP-1 is a hormone released naturally after eating; it slows the rate at which the stomach empties and signals the brain that food has arrived. Semaglutide mimics this signal in a sustained way across the week, which is why appetite falls and portion sizes often shrink without the person consciously trying to restrict.

In the STEP 1 clinical trial (published in the New England Journal of Medicine) adults with obesity taking 2.4mg semaglutide weekly alongside lifestyle changes lost an average of around 15% of body weight over 68 weeks. That figure comes from a randomised, controlled trial of nearly two thousand participants; it is robust evidence, and it is the basis on which NICE recommended Wegovy for use in the UK.

The pen travels through a dose titration before reaching 2.4mg. The schedule runs from 0.25mg through 0.5mg, 1.0mg, and 1.7mg, each held for approximately four weeks before stepping up. The reason for this gradual approach is tolerability: the gastrointestinal effects (nausea in particular) are directly linked to how quickly the dose climbs. Slower titration gives the gut time to adjust. Your prescriber, not the pen schedule itself, decides the exact timing; never accelerate a step without clinical input.

The NHS medicines page for semaglutide covers the full side-effect profile, storage conditions, and interactions in patient-friendly language and is worth bookmarking alongside the Patient Information Leaflet that comes with every pen.

Storage, disposal, and the practical realities of a weekly injection routine

The Wegovy pen needs to be kept refrigerated at 2–8°C before first use. Once you have started using a pen, the SmPC sets out exactly how long it can be kept at room temperature; always check the current leaflet for this figure rather than relying on a secondary source, since batch-specific guidance can vary. Keeping the pen in the fridge door (cool but not touching the back wall where temperatures can drop) works well for most people.

Each pen contains four weekly doses, capped individually. The pen locks automatically after the final dose. Used pens and needles are clinical waste and should go into a sharps container rather than the household bin; most GP surgeries and pharmacies accept sealed sharps bins for disposal.

If you miss a dose, the guidance is to inject as soon as you remember, provided your next scheduled dose is at least five days away. If it is closer than that, skip the missed dose and continue from the usual day. The Patient Information Leaflet is the authority on this; any uncertainty is worth raising with your prescribing team rather than guessing.

For anyone still deciding whether a weight loss injection is the right route, our page on the weight loss injection options we offer sets out the licensed options and what separates them.

Eligibility, side effects, and when to seek help

The UK licence for Wegovy covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. BMI alone is not the whole picture; a prescriber weighs up your full medical history, current medicines, and any conditions that might affect suitability. Being within the licensed BMI range is the starting point, not a guarantee of approval.

Side effects are dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, and reflux are the ones patients mention most. These are also the ones most likely to improve as your body adapts. The pattern almost always follows dose changes, worse in the first week or two after stepping up, then settling. Staying well hydrated matters; severe vomiting or diarrhoea that prevents fluid intake needs prompt medical attention because dehydration can affect kidney function.

There are rarer but more serious signals to know. Severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical review, the MHRA highlighted acute pancreatitis as a known, if infrequent, risk with GLP-1 medicines in a Drug Safety Update issued in January 2026. Gallbladder symptoms, signs of an allergic reaction, or sudden changes in vision should not be left to settle on their own. Any suspected side effect can be reported via the Yellow Card scheme.

If you are considering treatment and want to understand the broader landscape of what is available, including how the Novo weight loss injection fits within the options, our guide to weight loss injections explains the licensed treatments in detail, and the weight loss treatment overview is a useful starting point, and our FAQs page addresses the questions our prescribers hear most often. When you are ready to discuss your own situation, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, not a decision queue.